Retrophin Inc (NASDAQ:RTRX) Receives Consensus Rating of “Hold” from Analysts

Shares of Retrophin Inc (NASDAQ:RTRX) have been given an average recommendation of “Hold” by the ten research firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $45.67.

RTRX has been the topic of several recent analyst reports. ValuEngine lowered shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. TheStreet lowered shares of Retrophin from a “c-” rating to a “d+” rating in a research note on Friday, February 22nd. Barclays started coverage on shares of Retrophin in a research note on Monday, April 22nd. They issued an “overweight” rating and a $36.00 price target on the stock. William Blair restated an “outperform” rating on shares of Retrophin in a research report on Wednesday, April 17th. Finally, BidaskClub lowered shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Thursday, April 4th.

In other news, insider William E. Rote sold 1,625 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $17.77, for a total transaction of $28,876.25. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steve Aselage sold 3,676 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $17.81, for a total transaction of $65,469.56. Following the transaction, the director now owns 257,804 shares in the company, valued at $4,591,489.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,819 shares of company stock worth $194,503. Insiders own 4.32% of the company’s stock.



Several institutional investors and hedge funds have recently made changes to their positions in RTRX. Perceptive Advisors LLC grew its position in Retrophin by 4.0% in the 4th quarter. Perceptive Advisors LLC now owns 3,342,038 shares of the biopharmaceutical company’s stock valued at $49,782,000 after buying an additional 129,167 shares during the last quarter. Macquarie Group Ltd. grew its position in Retrophin by 10.3% in the 1st quarter. Macquarie Group Ltd. now owns 2,499,076 shares of the biopharmaceutical company’s stock valued at $56,555,000 after buying an additional 233,152 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Retrophin by 3.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 1,944,288 shares of the biopharmaceutical company’s stock valued at $43,999,000 after buying an additional 73,284 shares during the last quarter. Bank of America Corp DE grew its position in Retrophin by 114.4% in the 4th quarter. Bank of America Corp DE now owns 1,223,705 shares of the biopharmaceutical company’s stock valued at $27,693,000 after buying an additional 652,895 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Retrophin by 5.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,212,377 shares of the biopharmaceutical company’s stock valued at $27,437,000 after buying an additional 57,518 shares during the last quarter.

Shares of Retrophin stock opened at $18.96 on Wednesday. The company has a market capitalization of $795.65 million, a price-to-earnings ratio of -7.46 and a beta of 0.88. Retrophin has a 52 week low of $17.53 and a 52 week high of $33.00. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57.

Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.41). The company had revenue of $39.57 million during the quarter, compared to analysts’ expectations of $41.40 million. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) earnings per share. Analysts anticipate that Retrophin will post -3.02 EPS for the current fiscal year.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: Dollar Cost Averaging

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.